Skip to content

Dogwood Therapeutics DWTX Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$538.8M+20.8%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
-$21.34M+15.4%
Bioventus logo
BioventusBVS
-$23.14M-2,544%
Avanos Medical logo
Avanos MedicalAVNS
-$3.2M+89.0%

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's financing cash flow?
Dogwood Therapeutics (DWTX) reported financing cash flow of $11.29M in Q1 2026.
How has Dogwood Therapeutics's financing cash flow changed year-over-year?
Dogwood Therapeutics's financing cash flow increased by 53.2% year-over-year, from $7.37M to $11.29M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.